Pharmaceuticals and Biotech
Regulatory and reimbursement bottlenecks encouraging new business-models
The pharmaceutical industry is in a transformative phase with trends around value-based treatment, personalization and regulatory stringency. Evolving disease patterns towards chronic conditions in emerging markets, and aging population are other drivers for the industry. Companies are focusing more on R&D productivity, virtual clinical trials, and open innovation, while pricing pressures from biosimilars and generics remains a challenge.
Experience across the value chain
Our expertise across the product life cycle right from innovation R&D to Commercialization to life-cycle management will help you get a 360 degree view on future trends, market potential and positioning.
Experience across the value chain
Our expertise across the product life cycle right from innovation R&D to Commercialization to life-cycle management will help you get a 360 degree view on future trends, market potential and positioning.
Select coverage areas
- Clinical trial analytics
- MOA and Target Identification
- Epidemiology
- Indication landscape
- Technology scouting
- Gene therapy services
- Competitive landscape
- Literative analysis
- Evidence generation
Perspectives
Life Sciences
Unmet Needs and Challenges in Personalized Medicine ..
Cancer is a complex disease with a high economic burden and requires an effective treatment strategy. This evolving need for effective treatment is ad
Life Sciences
Aging Population_Impact on Healthcare & Its Man..
Rise in aging population is resulting in increased healthcare expenditure, as the elderly are prone to suffer from chronic conditions with acute episo
Life Sciences
Indications Priortization-Inflammation..
Leading pharmaceutical client conducted therapeutic area (TA) level analysis in order to select highly attractive inflammation indications . . .
The c
Few key questions clients are asking us in the area of Pharmaceuticals and Biotech
What are the different models for value-based treatments in oncology in US?
What are the technologies available for releasing antibiotics through joint replacement implants for 4-8 weeks?
What are strategies and productivity benchmarks of US & EU-5 based small and medium size companies for “virtual clinical trials” ?
How competitors have had overcome the price barriers by applying cost sharing models in the treatment of cancer and diabetes through insulin in ‘out-of-pocket’ geographies ?
What is the market potential and the addressable patient pools for a novel drug in hemophilia A across US and Japan?
Who are the suitable partners in terms of capability, innovation, portfolio, geographic reach etc. for vaccine production?
